Literature DB >> 24910174

Neonatal rhinovirus induces mucous metaplasia and airways hyperresponsiveness through IL-25 and type 2 innate lymphoid cells.

Jun Young Hong1, J Kelley Bentley2, Yutein Chung2, Jing Lei2, Jessica M Steenrod2, Qiang Chen2, Uma S Sajjan2, Marc B Hershenson3.   

Abstract

BACKGROUND: Early-life human rhinovirus infection has been linked to asthma development in high-risk infants and children. Nevertheless, the role of rhinovirus infection in the initiation of asthma remains unclear.
OBJECTIVE: We hypothesized that, in contrast to infection of mature BALB/c mice, neonatal infection with rhinovirus promotes an IL-25-driven type 2 response, which causes persistent mucous metaplasia and airways hyperresponsiveness.
METHODS: Six-day-old and 8-week-old BALB/c mice were inoculated with sham HeLa cell lysate or rhinovirus. Airway responses from 1 to 28 days after infection were assessed by using quantitative PCR, ELISA, histology, immunofluorescence microscopy, flow cytometry, and methacholine responsiveness. Selected mice were treated with a neutralizing antibody to IL-25.
RESULTS: Compared with mature mice, rhinovirus infection in neonatal mice increased lung IL-13 and IL-25 production, whereas IFN-γ, IL-12p40, and TNF-α expression was suppressed. In addition, the population of IL-13-secreting type 2 innate lymphoid cells (ILC2s) was expanded with rhinovirus infection in neonatal but not mature mice. ILC2s were the major cell type secreting IL-13 in neonates. Finally, anti-IL-25 neutralizing antibody attenuated ILC2 expansion, mucous hypersecretion, and airways responsiveness.
CONCLUSIONS: These findings suggest that early-life viral infection could contribute to asthma development by provoking age-dependent, IL-25-driven type 2 immune responses.
Copyright © 2014 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  Asthma; IL-25; mouse; neonatal; rhinovirus; type 2 innate lymphoid cells

Mesh:

Substances:

Year:  2014        PMID: 24910174      PMCID: PMC4119851          DOI: 10.1016/j.jaci.2014.04.020

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  51 in total

1.  Neonatal dendritic cells are intrinsically biased against Th-1 immune responses.

Authors:  C L Langrish; J C Buddle; A J Thrasher; D Goldblatt
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

2.  IL-4 utilizes an alternative receptor to drive apoptosis of Th1 cells and skews neonatal immunity toward Th2.

Authors:  Lequn Li; Hyun-Hee Lee; J Jeremiah Bell; Randal K Gregg; Jason S Ellis; Andre Gessner; Habib Zaghouani
Journal:  Immunity       Date:  2004-04       Impact factor: 31.745

3.  Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.

Authors:  N Sigurs; R Bjarnason; F Sigurbergsson; B Kjellman
Journal:  Am J Respir Crit Care Med       Date:  2000-05       Impact factor: 21.405

4.  Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity.

Authors:  Ya-Jen Chang; Hye Young Kim; Lee A Albacker; Nicole Baumgarth; Andrew N J McKenzie; Dirk E Smith; Rosemarie H Dekruyff; Dale T Umetsu
Journal:  Nat Immunol       Date:  2011-05-29       Impact factor: 25.606

5.  Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848.

Authors:  Ofer Levy; Kol A Zarember; Rene M Roy; Colette Cywes; Paul J Godowski; Michael R Wessels
Journal:  J Immunol       Date:  2004-10-01       Impact factor: 5.422

6.  Season of infant bronchiolitis and estimates of subsequent risk and burden of early childhood asthma.

Authors:  Kecia N Carroll; Pingsheng Wu; Tebeb Gebretsadik; Marie R Griffin; William D Dupont; Edward F Mitchel; Tina V Hartert
Journal:  J Allergy Clin Immunol       Date:  2009-01-31       Impact factor: 10.793

7.  Defective macrophage function in neonates and its impact on unresponsiveness of neonates to polysaccharide antigens.

Authors:  R L Chelvarajan; S M Collins; I E Doubinskaia; S Goes; J Van Willigen; D Flanagan; W J S De Villiers; J S Bryson; S Bondada
Journal:  J Leukoc Biol       Date:  2004-02-24       Impact factor: 4.962

8.  Host and viral factors associated with severity of human rhinovirus-associated infant respiratory tract illness.

Authors:  E Kathryn Miller; John V Williams; Tebeb Gebretsadik; Kecia N Carroll; William D Dupont; Yassir A Mohamed; Laura-Lee Morin; Luke Heil; Patricia A Minton; Kimberly Woodward; Zhouwen Liu; Tina V Hartert
Journal:  J Allergy Clin Immunol       Date:  2011-01-26       Impact factor: 10.793

9.  A defect in nucleosome remodeling prevents IL-12(p35) gene transcription in neonatal dendritic cells.

Authors:  Stanislas Goriely; Carine Van Lint; Réza Dadkhah; Myriam Libin; Dominique De Wit; Dominique Demonté; Fabienne Willems; Michel Goldman
Journal:  J Exp Med       Date:  2004-03-29       Impact factor: 14.307

10.  Rhinovirus-induced wheezing in infancy--the first sign of childhood asthma?

Authors:  Anne Kotaniemi-Syrjänen; Raija Vainionpää; Tiina M Reijonen; Matti Waris; Kaj Korhonen; Matti Korppi
Journal:  J Allergy Clin Immunol       Date:  2003-01       Impact factor: 10.793

View more
  82 in total

Review 1.  Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma.

Authors:  Amy S Feldman; Yuan He; Martin L Moore; Marc B Hershenson; Tina V Hartert
Journal:  Am J Respir Crit Care Med       Date:  2015-01-01       Impact factor: 21.405

2.  Reply: Toward Primary Prevention of Asthma: Role of Corticosteroids for the First Rhinovirus Wheeze.

Authors:  Tina Hartert; Marc Hershenson
Journal:  Am J Respir Crit Care Med       Date:  2015-10-15       Impact factor: 21.405

Review 3.  Environmental exposures and mechanisms in allergy and asthma development.

Authors:  Liza Bronner Murrison; Eric B Brandt; Jocelyn Biagini Myers; Gurjit K Khurana Hershey
Journal:  J Clin Invest       Date:  2019-02-11       Impact factor: 14.808

4.  The Innate Cytokines IL-25, IL-33, and TSLP Cooperate in the Induction of Type 2 Innate Lymphoid Cell Expansion and Mucous Metaplasia in Rhinovirus-Infected Immature Mice.

Authors:  Mingyuan Han; Charu Rajput; Jun Y Hong; Jing Lei; Joanna L Hinde; Qian Wu; J Kelley Bentley; Marc B Hershenson
Journal:  J Immunol       Date:  2017-07-12       Impact factor: 5.422

Review 5.  Innate lymphoid cells: major players in inflammatory diseases.

Authors:  Mikaël Ebbo; Adeline Crinier; Frédéric Vély; Eric Vivier
Journal:  Nat Rev Immunol       Date:  2017-08-14       Impact factor: 53.106

Review 6.  Lessons learned from birth cohort studies conducted in diverse environments.

Authors:  Daniel J Jackson; James E Gern; Robert F Lemanske
Journal:  J Allergy Clin Immunol       Date:  2017-02       Impact factor: 10.793

7.  Clinical definition of respiratory viral infections in young children and potential bronchiolitis misclassification.

Authors:  Rosemary Megalaa; Geovanny F Perez; Sasikumar Kilaikode-Cheruveettara; Nidhi Kotwal; Carlos E Rodriguez-Martinez; Gustavo Nino
Journal:  J Investig Med       Date:  2017-09-24       Impact factor: 2.895

8.  Rhinovirus-induced airway cytokines and respiratory morbidity in severely premature children.

Authors:  Geovanny F Perez; Krishna Pancham; Shehlanoor Huseni; Amisha Jain; Carlos E Rodriguez-Martinez; Diego Preciado; Mary C Rose; Gustavo Nino
Journal:  Pediatr Allergy Immunol       Date:  2015-03       Impact factor: 6.377

Review 9.  Influences on allergic mechanisms through gut, lung, and skin microbiome exposures.

Authors:  Andrea M Kemter; Cathryn R Nagler
Journal:  J Clin Invest       Date:  2019-02-25       Impact factor: 14.808

Review 10.  Insights into Group 2 Innate Lymphoid Cells in Human Airway Disease.

Authors:  Maya R Karta; David H Broide; Taylor A Doherty
Journal:  Curr Allergy Asthma Rep       Date:  2016-01       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.